Thermo Fisher Scientific Inc. (TMO) News
Filter TMO News Items
TMO News Results
|Loading, please wait...|
TMO News Highlights
- For TMO, its 30 day story count is now at 70.
- Over the past 23 days, the trend for TMO's stories per day has been choppy and unclear. It has oscillated between 1 and 18.
- The most mentioned tickers in articles about TMO are MRNA, AMP and BIO.
Latest TMO News From Around the Web
Below are the latest news stories about Thermo Fisher Scientific Inc that investors may wish to consider to help them evaluate TMO as an investment opportunity.
Thermo Fisher's (TMO) strong pandemic response stance enables it to accelerate its growth strategy, and bump up investments, which encourages it to raise the 2022 core organic growth guidance.
In this article, we discuss 10 companies that just increased their dividends by over 10%. If you want to skip our detailed analysis of these stocks, go directly to These 5 Companies Just Increased Their Dividends By Over 10%. The S&P 500 is heading into correction territory as the Russian attack on Ukraine has severely […]
Scientific instrumentation and software services provider Thermo Fisher Scientific Inc. (NYSE: TMO) recently announced a quarterly dividend of $0.30 per share, a 15.4% increase from the previous dividend of $0.26 per share. The dividend will be paid on April 14, 2022, to shareholders of record as of March 16, 2022. The company’s annual dividend of $1.2 per share now reflects a dividend yield of 0.2% based on Wednesday’s closing price. Notably, the company has been raising its dividend consistently over the past four years, making it an attractive choice for investors. Stock Rating Recently, Cowen & Co.analyst Daniel Brennan reiterated a Buy rating on the stock.
Thermo Fisher Scientific, Inc. (TMO) provides analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services segments. I am neutral on TMO stock. Its profitability is consistent and strong, but there is a high level of debt, as the company significantly increased its long-term debt in 2021, and the latest fourth-quarter 2021 results were mixed. Investors looking for dividend stocks most probably will not get excited by the minimal dividend yield of Thermo Fisher Scientific. However, the firm's strong financial performance may still make the stock appealing to investors.
One sign of the ever-evolving life sciences scene in the Triangle: There have been at least a dozen mergers and acquisitions that have involved either a Triangle-owned CRO or one with a major local presence in just the past year.
The Massachusetts life sciences industry is rife with companies developing drugs and devices to tackle serious diseases, inking new partnership deals, raising money, expanding facilities and more.
Thermo Fisher Scientific (TMO) declares $0.30/share quarterly dividend, 15% increase from prior dividend of $0.26.
Moderna (MRNA) and Thermo Fisher Scientific (TMO) have inked a 15-year strategic collaboration agreement. Read more on its details.
Moderna Inc (NASDAQ: MRNA ) has entered into a long-term agreement with Thermo Fisher Scientific Inc (NYSE: TMO ) to manufacture its COVID-19 vaccine and other experimental medicines based on mRNA technology. Thermo Fisher had already partnered with Moderna last year to help scale up production of its COVID vaccine, … Full story available on Benzinga.com
Moderna Inc has entered into a long-term agreement with Thermo Fisher Scientific for the manufacturing of its COVID-19 vaccine and other experimental medicines based on mRNA technology, the companies said on Wednesday.